Fulltext

Activity of a Novel bcl-2/bcl-xL-Bispecific Antisense Oligonucleotide Against Tumors of Diverse Histologic Origins

Gautschi, Oliver ; Tschopp, Stefan ; Olie, Robert A. ; Leech, Siân H. ; Simões-Wüst, A. Paula ; Ziegler, Annemarie ; Baumann, Bettina ; Odermatt, Bernhard ; Hall, Jonathan ; Stahel, Rolf A. ; Zangemeister-Wittke, Uwe

In: Journal of the National Cancer Institute, 2001, vol. 93, no. 6, p. 463-471

Ajouter à la liste personnelle
    Titre
    • Activity of a Novel bcl-2/bcl-xL-Bispecific Antisense Oligonucleotide Against Tumors of Diverse Histologic Origins
    Auteur
    • Gautschi, Oliver. Affiliations of authors: O. Gautschi, S. Tschopp, R. A. Olie, S. H. Leech, A. P. Simões-Wüst, A. Ziegler, R. A. Stahel, U. Zangemeister-Wittke (Division of Oncology, Department of Internal Medicine), B. Odermatt (Department of Pathology), University Hospital, Zurich, Switzerland; B. Baumann, Institute of Biochemistry, Swiss Federal Institute of Technology, Zurich; J. Hall, Novartis Pharma AG, Basel, Switzerland.
    • Tschopp, Stefan. Affiliations of authors: O. Gautschi, S. Tschopp, R. A. Olie, S. H. Leech, A. P. Simões-Wüst, A. Ziegler, R. A. Stahel, U. Zangemeister-Wittke (Division of Oncology, Department of Internal Medicine), B. Odermatt (Department of Pathology), University Hospital, Zurich, Switzerland; B. Baumann, Institute of Biochemistry, Swiss Federal Institute of Technology, Zurich; J. Hall, Novartis Pharma AG, Basel, Switzerland.
    • Olie, Robert A.. Affiliations of authors: O. Gautschi, S. Tschopp, R. A. Olie, S. H. Leech, A. P. Simões-Wüst, A. Ziegler, R. A. Stahel, U. Zangemeister-Wittke (Division of Oncology, Department of Internal Medicine), B. Odermatt (Department of Pathology), University Hospital, Zurich, Switzerland; B. Baumann, Institute of Biochemistry, Swiss Federal Institute of Technology, Zurich; J. Hall, Novartis Pharma AG, Basel, Switzerland.
    • Leech, Siân H.. Affiliations of authors: O. Gautschi, S. Tschopp, R. A. Olie, S. H. Leech, A. P. Simões-Wüst, A. Ziegler, R. A. Stahel, U. Zangemeister-Wittke (Division of Oncology, Department of Internal Medicine), B. Odermatt (Department of Pathology), University Hospital, Zurich, Switzerland; B. Baumann, Institute of Biochemistry, Swiss Federal Institute of Technology, Zurich; J. Hall, Novartis Pharma AG, Basel, Switzerland.
    • Simões-Wüst, A. Paula. Affiliations of authors: O. Gautschi, S. Tschopp, R. A. Olie, S. H. Leech, A. P. Simões-Wüst, A. Ziegler, R. A. Stahel, U. Zangemeister-Wittke (Division of Oncology, Department of Internal Medicine), B. Odermatt (Department of Pathology), University Hospital, Zurich, Switzerland; B. Baumann, Institute of Biochemistry, Swiss Federal Institute of Technology, Zurich; J. Hall, Novartis Pharma AG, Basel, Switzerland.
    • Ziegler, Annemarie. Affiliations of authors: O. Gautschi, S. Tschopp, R. A. Olie, S. H. Leech, A. P. Simões-Wüst, A. Ziegler, R. A. Stahel, U. Zangemeister-Wittke (Division of Oncology, Department of Internal Medicine), B. Odermatt (Department of Pathology), University Hospital, Zurich, Switzerland; B. Baumann, Institute of Biochemistry, Swiss Federal Institute of Technology, Zurich; J. Hall, Novartis Pharma AG, Basel, Switzerland.
    • Baumann, Bettina. Affiliations of authors: O. Gautschi, S. Tschopp, R. A. Olie, S. H. Leech, A. P. Simões-Wüst, A. Ziegler, R. A. Stahel, U. Zangemeister-Wittke (Division of Oncology, Department of Internal Medicine), B. Odermatt (Department of Pathology), University Hospital, Zurich, Switzerland; B. Baumann, Institute of Biochemistry, Swiss Federal Institute of Technology, Zurich; J. Hall, Novartis Pharma AG, Basel, Switzerland.
    • Odermatt, Bernhard. Affiliations of authors: O. Gautschi, S. Tschopp, R. A. Olie, S. H. Leech, A. P. Simões-Wüst, A. Ziegler, R. A. Stahel, U. Zangemeister-Wittke (Division of Oncology, Department of Internal Medicine), B. Odermatt (Department of Pathology), University Hospital, Zurich, Switzerland; B. Baumann, Institute of Biochemistry, Swiss Federal Institute of Technology, Zurich; J. Hall, Novartis Pharma AG, Basel, Switzerland.
    • Hall, Jonathan. Affiliations of authors: O. Gautschi, S. Tschopp, R. A. Olie, S. H. Leech, A. P. Simões-Wüst, A. Ziegler, R. A. Stahel, U. Zangemeister-Wittke (Division of Oncology, Department of Internal Medicine), B. Odermatt (Department of Pathology), University Hospital, Zurich, Switzerland; B. Baumann, Institute of Biochemistry, Swiss Federal Institute of Technology, Zurich; J. Hall, Novartis Pharma AG, Basel, Switzerland.
    • Stahel, Rolf A.. Affiliations of authors: O. Gautschi, S. Tschopp, R. A. Olie, S. H. Leech, A. P. Simões-Wüst, A. Ziegler, R. A. Stahel, U. Zangemeister-Wittke (Division of Oncology, Department of Internal Medicine), B. Odermatt (Department of Pathology), University Hospital, Zurich, Switzerland; B. Baumann, Institute of Biochemistry, Swiss Federal Institute of Technology, Zurich; J. Hall, Novartis Pharma AG, Basel, Switzerland.
    • Zangemeister-Wittke, Uwe. Affiliations of authors: O. Gautschi, S. Tschopp, R. A. Olie, S. H. Leech, A. P. Simões-Wüst, A. Ziegler, R. A. Stahel, U. Zangemeister-Wittke (Division of Oncology, Department of Internal Medicine), B. Odermatt (Department of Pathology), University Hospital, Zurich, Switzerland; B. Baumann, Institute of Biochemistry, Swiss Federal Institute of Technology, Zurich; J. Hall, Novartis Pharma AG, Basel, Switzerland.
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Journal of the National Cancer Institute, 2001, vol. 93, no. 6, p. 463-471. Oxford University Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:294735
    Summary
    Background: Increased expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL is involved in the development and progression of many tumors. We recently reported that the bcl-2/bcl-xL-bispecific antisense oligonucleotide 4625 induces apoptosis in lung carcinoma cells. To further assess the therapeutic potential of oligonucleotide 4625, we investigated its effect on a series of human tumor cell lines of diverse histologic origins in vitro and in vivo. Methods: Oligonucleotide 4625-mediated inhibition of bcl-2 and bcl-xL expression in vitro was measured in breast carcinoma cells with the use of reverse transcription-polymerase chain reaction (PCR), real-time PCR, and western blotting. Cytotoxicity was assessed in several different cell lines by measurement of tumor cell growth, propidium iodide uptake, and nuclear apoptosis. The in vivo activity of oligonucleotide 4625 was determined by the inhibition of growth of established tumor xenografts in nude mice, immunohistochemical staining of Bcl-2 and Bcl-x proteins in the tumors, and western blotting of tumor lysates. Apoptosis in tumor xenografts was detected with the use of in situ TUNEL (i.e., terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-digoxigenin nick end labeling) staining. All statistical tests are two-sided. Results: In breast carcinoma cells, oligonucleotide 4625 treatment reduced bcl-2 and bcl-xL messenger RNA levels in a dose-dependent manner. At 600 nM, oligonucleotide 4625 reduced Bcl-2 and Bcl-xL protein levels to 25% (95% confidence interval [CI] = 16% to 34%) and 20% (95% CI = 14% to 26%), respectively, of the levels in untreated cells and it decreased viability in all cell lines mainly by inducing apoptosis. In vivo, oligonucleotide 4625 statistically significantly inhibited the growth of breast and colorectal carcinoma xenografts by 51% (95% CI = 28% to 74%) and 59% (95% CI = 44% to 74%), respectively, relative to those treated with control oligonucleotide 4626; it also reduced Bcl-2 and Bcl-xL protein levels and induced tumor cell apoptosis. Conclusion: The bcl-2/bcl-xL-bispecific antisense oligonucleotide 4625 merits further study as a novel compound for cancer therapy